Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$BEAT HeartBeam Inc focuses on developing & commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting
https://heartbeam.com
This is really cool technology...and looks convenient and easy to use.
$BEAT
$BEAT HeartBeam, Inc’s breakthrough solution employs a reusable, credit card sized, 3D vector ECG recording device and cloud-based software capable of assisting a physician in diagnosing a wide range of cardiovascular disease
https://ir.heartbeam.com/
It's trading just over 25% of its 10-day average volume as we head into the close... but UP almost 5%.
$BEAT
These new studies demonstrating increased risk of heart attack or other dangerous cardiac events underscore the importance of new advancements in cardiac monitoring such as the BEAT technology provides. With everyone working harder and longer today than ever before, stress factors including insomnia will only become more prevalent. The BEAT technology can play increasingly important role in keeping people with existing heart conditions safer and living better lives.
The LIVMOR acquisition Extends HeartBeam’s Reach with FDA-cleared Halo+™ Atrial Fibrillation Detection System and Physician-prescribed Integrated Patient Care Platform
$BEAT
This was a very interesting article...
$BEAT
$BEAT Occupational physical activity raises heart disease risk in men, but not women.
https://t.co/qK2BmYjELn
Occupational physical activity raises heart disease risk in men, but not women https://t.co/qK2BmYjELn
— HeartBeam, Inc. (@HeartBeamInc) March 20, 2023
This is a very interesting technology and sounds like a great product to help reduce heart attacks...
$BEAT
This was a great acquisition...
Acquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System
$BEAT
$BEAT Study: Insomnia Linked to Increased Risk of Heart Attack, Especially for Women
https://health.com/insomnia-heart-attack-7368320?utm_source=twitter&utm_medium=social&utm_campaign=shareurlbuttons via
@health_com_
Study: Insomnia Linked to Increased Risk of Heart Attack, Especially for Women https://t.co/yb1KyomUip via @health_com_
— HeartBeam, Inc. (@HeartBeamInc) March 23, 2023
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
$BEAT Acquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System; HeartBeam Reports Fourth Quarter and Full Year 2022 Financial Results https://finance.yahoo.com/news/heartbeam-reports-fourth-quarter-full-200100156.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: $BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI™ is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
$BEAT News March 20, 2023
HeartBeam, Inc. (NASDAQ:BEAT) Q4 2022 Earnings Call Transcript
https://finance.yahoo.com/news/heartbeam-inc-nasdaq-beat-q4-070607632.html
Very significant acquisition...
Under the terms of the acquisition agreement, HeartBeam purchased LIVMOR’s intellectual property for an undisclosed amount, including 3 issued United States patents, LIVMOR technology, including the Halo AF Detection System, LIVMORs business contracts and relationships as well as all Samsung watch and tablet inventory. Additionally, HeartBeam hired LIVMOR’s key technical employees.
$BEAT
Some pretty significant accomplishments and developments
Acquired Assets from LIVMOR, Extending Reach in Remote Monitoring and Detection with an Existing Cutting Edge FDA-Cleared Product, Halo+™ Atrial Fibrillation Detection System
Partnered with Evolve Manufacturing to Build HeartBeam AIMIGo 12-Lead 3D Vector Electrocardiogram Device
Received European Patent for HeartBeam AIMIGo Technology
Initial FDA Submission of HeartBeam AIMIGo™, the Telehealth Solution, Projected for Q2 2023
$BEAT
$BEAT $2.40 +5.73% HeartBeam, Inc. (NASDAQ:BEAT) Q4 2022 Earnings Call Transcript March 17, 2023
https://finance.yahoo.com/news/heartbeam-inc-nasdaq-beat-q4-070607632.html
HeartBeam Announces Acquisition of LIVMOR Assets; Extends HeartBeam’s Reach with FDA-cleared Halo+™ Atrial Fibrillation Detection System and Physician-prescribed Integrated Patient Care Platform https://finance.yahoo.com/news/heartbeam-announces-acquisition-livmor-assets-123100675.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance $BEAT
HeartBeam Reports Fourth Quarter and Full Year 2022 Financial Results
News Link:
https://www.businesswire.com/news/home/20230316005691/en/HeartBeam-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results
5.15 top came back later
Finnair bust 6$
Got interesting again
Good job....Artificial mini pump on low volume
Flipped out at 4.04 from 3.58 entry
Chart looks like running a few more days
https://stockcharts.com/h-sc/ui?s=beat
27000 SHARE BUY. LITTLE MONSTER HERE BOYS $$$$$$$$$$$$$$$$$
3.30s yesssss
Slow grind down
Yess come on down
Looks like head n shoulders coming and then 3s and maybe 2s
That would be nice
Waiting for 3.30s and 2.42s
It’s all good Ill let this stew and buy some at the lows
Nov 13th is the vote for it lol read the filings it's on ihub
Oh shit they didnt amend that? This is going to get crushed
Headed to 3.30 they want to increase authorize shares to 100milly
And she is officially toast fell past 4.50s get ready for 3s or maybe 2s
Weeeee collapse come on 3s
Fell below the .618 looking at 3.27 to buy back in....Collapse baby Collapse
Lmfao learn how to trade the daily is overbought....Better to see if 3s hold
Toast 3.30s tomorrow
Not a gift if 4.50 doesn't hold up...Got out Friday looking for a rentry if 4.50 holds if not I'll wait for high 2s
Followers
|
9
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
338
|
Created
|
07/01/09
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |